University of Nottingham – Confidence in Concept 2019
Lead Research Organisation:
University of Nottingham
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Organisations
Publications
Latif A
(2024)
Microparticles Decorated with Cell-Instructive Surface Chemistries Actively Promote Wound Healing.
in Advanced materials (Deerfield Beach, Fla.)
Anyiam O
(2024)
Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus.
in Clinical nutrition (Edinburgh, Scotland)
Kirk T
(2025)
Stochastic variational inference improves quantification of multiple timepoint arterial spin labelling perfusion MRI
in Frontiers in Neuroscience
| Description | Designing bio-instructive materials for translation ready medical devices |
| Amount | £4,074,945 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 01/2027 |
| Description | Evaluation and optimisation of new engineered human human apoferritins: protein nanocages for targeted drug delivery and intracellular cargo release |
| Amount | £1,577,196 (GBP) |
| Funding ID | BB/Y008200/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 03/2026 |
| Description | ICURe Award to Prof. Chappell |
| Amount | £31,337 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Impact Accelerator Award to Prof. Shaw / Dr Clifford |
| Amount | £19,000 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 06/2022 |
| End | 07/2023 |
| Description | Innovate UK award to Prof. Chappell and Dr. Kirk |
| Amount | £295,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC DPGF award to Dr. Lisa White |
| Amount | £300,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Realtime wireless monitoring of inflammation for improved healthcare outcomes |
| Amount | £960,320 (GBP) |
| Funding ID | MR/Z505821/1 |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2024 |
| End | 09/2026 |
| Description | SBRI grant to Quantified Imaging |
| Amount | £313,000 (GBP) |
| Organisation | Small Business Research Initiative (SBRI) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | UoN IAA award to Prof. Chappell |
| Amount | £49,000 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Title | DISRUPTION OF EPITHELIAL BARRIERS FOR MOLECULAR DELIVERY ENHANCEMENT OR EXTRACTION OF EXTRACELLULAR FLUIDS |
| Description | The invention provides a method of delivering a payload molecule across an epithelial tissue barrier, the method comprising: applying the payload molecule to the epithelial tissue barrier, and additionally applying an agent to the epithelial tissue barrier. The agent is (i) a microbial quorum sensing signalling molecule (microbial QSSM) or a derivative or variant thereof, which is capable of disrupting the epithelial tissue barrier function, or (ii) a carboxylic acid compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof. |
| IP Reference | WO2024009101 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2024 |
| Licensed | No |
| Impact | None as yet |
| Title | VEGF ANTIBODIES |
| Description | The present invention relates to anti-VEGF-A165b antibodies. The invention also relates to pharmaceutical compositions, kits and methods of use in therapy. |
| IP Reference | WO2024079482 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2024 |
| Licensed | No |
| Company Name | IsomAb |
| Description | IsomAb develops isoform specific antibodies. |
| Year Established | 2022 |
| Impact | IsomAb is a pre-clinical stage company with Proof-of-Concept data, in two animal models, and an ambitious plan to take its first product into the clinic by 2026. |
| Website | http://isomab.bio |